期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 261, 期 1-2, 页码 29-36出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2013.04.018
关键词
Alemtuzumab; Immune status; CD52; Multiple sclerosis
Alemtuzumab is a monoclonal antibody against the CD52 antigen present at high levels on the surface of lymphocytes. While treatment of multiple sclerosis patients with alemtuzumab results in marked depletion of lymphocytes from the circulation, it has not been associated with a high incidence of serious infections. In a human CD52 transgenic mouse, alemtuzumab treatment showed minimal impact on the number and function of innate immune cells. A transient decrease in primary adaptive immune responses was observed post-alemtuzumab but there was little effect on memory responses. These results potentially help explain the level of immunocompetence observed in alemtuzumab-treated MS patients. (C) 2013 The Authors. Published by Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据